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Abstract
Background: Impaired levels or function of C1 inhibitor (C1- INH) results in angioedema 
due to increased bradykinin. It is important to distinguish between angioedema related 
to C1- INH deficiency and that caused by other mechanisms, as treatment options are 
different.	In	hereditary	(HAE)	and	acquired	(AAE)	angioedema,	C1-	INH	concentration	
is measured to aid patient diagnosis. Here, we describe an automated turbidimetric 
assay to measure C1- INH concentration on the Optilite® analyzer.
Methods: Linearity, precision, and interference were established over a range of C1- 
INH concentrations. The 95th percentile reference interval was generated from 120 
healthy adult donors. To compare the Optilite C1- INH assay with a predicate assay 
used in a clinical laboratory, samples sent for C1- INH investigation were used. The 
predicate results were provided to allow comparison.
Results: The Optilite C1- INH assay was linear across the measuring range at the stand-
ard sample dilution. Intra and interassay variability was <6%. The 95th percentile adult 
reference interval for the assay was 0.21- 0.38 g/L. There was a strong correlation 
between the Optilite concentrations and those generated with the predicate assay 
(R2 = 0.94, P < 0.0001, slope y = 0.83x).	All	patients	with	Type	I	HAE	(n	=	24)	and	AAE	
(n = 3) tested had concentrations below the measuring range in both assays, while all 
patients	with	unspecified	angioedema	 (UAE),	 not	diagnosed	with	HAE	or	AAE	had	
values within the reference range.
Conclusion:	The	Optilite	assay	allows	the	automated	and	precise	quantification	of	
C1- INH concentrations in patient samples. It could therefore be used as a tool to aid 
the investigation of patients with angioedema.
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1  | INTRODUC TION
C1- INH (C1 inhibitor, C1 inactivator) is a protease inhibitor which 
functions to control spontaneous activation of the classical comple-
ment pathway, as well as proteases of the fibrinolytic, clotting, and 
kinin pathways.1,2 The key role of C1- INH in regulating these path-
ways means that a C1- INH deficiency or impaired C1- INH function 
results in consumption of the early classical complement pathway 
proteins (C2 and C4)3 as well as increased concentrations of the 
vasoactive peptide bradykinin.4,5 Increased bradykinin leads to va-
sodilation, fluid extravasation, increased capillary permeability and 
ultimately angioedema.5
Angioedema	 can	 be	 split	 into	 two	 main,	 broad	 subtypes—
bradykinin- induced angioedema and histamine- induced an-
gioedema. Bradykinin- induced angioedema can be caused by an 
abnormal concentration or function of C1- INH, as well as mutations 
in	 FXII	 and	 treatment	 with	 angiotensin-	converting	 enzyme	 (ACE)	
inhibitors.6 These bradykinin- mediated forms of angioedema are 
distinct from histamine- induced angioedema stemming from allergic 
reactions, as they do not respond to conventional therapies such as 
antihistamines or corticosteroids.7-9 This is crucial when deciding the 
appropriate treatment for patients presenting with angioedema.
Angioedema	due	to	abnormal	concentrations	or	function	of	C1-	
INH	 may	 be	 hereditary	 (C1-	INH-	HAE)	 or	 acquired	 (C1-	INH-	AAE,	
from	here	on	in,	abbreviated	to	HAE	and	AAE).	The	measurement	of	
C1- INH concentration and function helps differentiate between an-
gioedema due to impaired C1- INH production or function, and that 
caused by other mechanisms.10,11
Hereditary angioedema is a rare, genetic disorder, which in 
the majority of patients is due to mutations in the SERPING1 gene. 
Diagnosis	of	HAE	is	primarily	made	on	biochemical	testing.	The	dis-
ease is characterized by recurrent, nonurticarial, unpredictable epi-
sodes of swelling classically affecting the skin, gastrointestinal tract 
and airway. Gastrointestinal attacks of swelling can cause severe 
abdominal pain, nausea and vomiting12,13 and may last from hours 
to	 days.	 Attacks	 of	 laryngeal	 angioedema	 are	 life-	threatening	 and	
require	urgent	treatment.14
There	 are	 two	 forms	 of	 HAE	 with	 C1-	INH	 deficiency—Type	 I,	
which is characterized by very low C1- INH concentrations, and Type 
II, which is characterized by a normal or elevated C1- INH concentra-
tion with reduced function, usually due to mutations in exon eight 
which affect target binding.11	Prevalence	of	HAE	 is	approximately	
1	 in	 50	000	 individuals,	with	 around	 85%	having	 Type	 I	HAE.15-19 
Notably,	 there	 is	 no	 family	 history	 of	 HAE	 in	 20%-	25%	 of	 cases	
which are due to de novo mutations in SERPING1.
There	are	significant	delays	 in	the	diagnosis	of	HAE,18-20 with 
one UK study reporting an average delay of 10 years for Type I di-
agnosis	and	18	years	for	Type	II	HAE.20 This is a great cause for con-
cern, because a diagnostic delay or incorrect diagnosis can lead to 
inappropriate and ineffective treatment, unnecessary (and poten-
tially disease exacerbating) exploratory surgeries in patients with 
abdominal swelling and pain presenting as an acute abdomen, and 
may be fatal if appropriate treatment is not promptly administered 
to	patients	with	a	laryngeal	edema	attack.	A	recent	study	reported	
29%	mortality	 in	undiagnosed	HAE	patients,	compared	with	only	
3% in those who had appropriate diagnoses.21	Accurate	and	timely	
diagnosis	of	HAE	is	therefore	crucial	to	ensure	patients	receive	the	
necessary treatment and the disease is managed appropriately. In 
addition to C1- INH protein concentration and function, the mea-
surement of C4 is important in the biochemical diagnostic assess-
ment	of	HAE,	and	is	reduced	in	Type	1	and	Type	2	HAE	as	well	as	
AAE.15,22,23
The	clinical	presentation	of	AAE	due	to	C1-	INH	deficiency	is	very	
similar	to	that	of	HAE,	but	the	age	of	onset	of	symptoms	is	much	later	
(by	the	second	decade	of	life	for	90%	of	HAE	patients,	but	after	the	
fourth	decade	of	life	for	the	majority	of	AAE	patients).24,25 In most pa-
tients,	AAE	due	to	C1-	INH	deficiency	is	associated	with	the	presence	
of neutralizing C1- INH autoantibodies and/or lymphoproliferative dis-
ease.	Diagnosis	of	AAE	is	predominantly	based	on	the	same	biochemi-
cal	tests	as	HAE;	C1-	INH	protein	concentration,	C4	concentration	and	
C1- INH functional tests, but with the addition of anti- C1- INH anti-
body	testing	and	C1q	concentrations.	Similarly	to	HAE,	around	20%	of	
patients have normal antigenic levels of C1- INH, but reduced function. 
A	normal	C1-	INH	concentration,	therefore,	does	not	exclude	a	diag-
nosis	of	HAE	or	AAE;	however,	C4	would	be	predicted	to	be	reduced	
in both conditions.24
Type	I	HAE	and	AAE	with	 low	C1-	INH	concentration	are	the	
most	 common	 forms	of	 the	diseases.	A	 simple,	 fast	 and	 reliable	
test to measure the concentration of C1- INH is therefore an in-
valuable tool to aid in the diagnosis of these patients. Here, we 
describe a fully automated, turbidimetric assay for the measure-
ment of C1- INH protein concentration on the Optilite® turbidi-
metric analyzer.
2  | MATERIAL S AND METHODS
2.1 | Serum samples
Serum samples were obtained from several sources for these studies.
2.1.1 | Analytical studies
Serum samples from healthy adult blood donors were purchased 
from Quest Biomedical (Solihull, UK). Sample collection was ap-
proved	by	the	Institution	Ethics	Review	Board	(#05142),	with	all	do-
nors providing written informed consent. These samples were used 
for development of the normal adult reference interval (n = 120, 60 
male:60 female, age range 23- 94 years).
For assay validation experiments, sera were obtained from two 
main sources: (a) sera from healthy volunteers were purchased 
from Seralab, UK and (b) deidentified remnants of serum speci-
mens collected for routine diagnostic testing, which were used in 
accordance	 with	 the	 World	 Medical	 Association	 Declaration	 of	
Helsinki-	Ethical	Principles	for	Medical	Research	Involving	Human	
Subjects 1964.
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2.1.2 | Assay comparisons
Residual, anonymous clinical samples, together with their serum C1- 
INH concentration and function measurements determined by rou-
tine clinical assay, were obtained from the Immunodeficiency Centre 
for Wales and Department of Immunology, Barts Health NHS Trust 
(n = 260, age range 1- 87 years). The C1- INH protein concentration 
and	function	results	generated	offsite	in	UKAS	accredited	immunol-
ogy laboratories were provided to allow comparisons.
2.2 | Sample preparation
Blood samples were collected by venepuncture, allowed to clot nat-
urally and then the serum separated to prevent hemolysis. Samples 
were	stored	at	−20°C	before	testing.
2.3 | Development of C1- INH- specific antiserum
Sheep anti- human C1- INH antiserum was generated by subcuta-
neous immunization with 50 μg of purified human C1- INH antigen 
(Calbiochem) mixed with complete Freund’s adjuvant, with subse-
quent	boosting	at	monthly	intervals	with	10	μg antigen in incomplete 
Freund’s adjuvant.
To	assess	specificity	of	 the	C1-	INH	antiserum,	10%	SDS-	PAGE	
gels were loaded with pure C1- INH or one of ten other plasma pro-
teins; Factor XIa, Factor XIIa, Kallikrein, C1r, C1s, C2, C3c, C4, Factor 
B or Properdin. 0.5 μg of each protein was added for western blot-
ting with the C1- INH antiserum; 2 μg of each protein was added for 
Coomassie blue staining.
2.4 | Development of C1- INH- depleted antiserum
Pooled serum was loaded on a CaptureSelect™	C1-	inhibitor	Affinity	
Matrix column (Thermofisher, UK) to allow adsorption of C1- INH 
protein.	Effluent	was	collected	and	the	absence	of	C1-	INH	protein	
confirmed	by	10%	SDS-	PAGE	and	western	blotting.	Where	low-	level	
C1-	INH	samples	were	required,	depleted	serum	was	used	for	dilut-
ing samples.
2.5 | Measurement of C1- INH
Unless otherwise stated, C1- INH concentrations were determined 
using the Optilite C1 Inactivator Kit (NK019.OPT) on the Optilite tur-
bidimetric analyzer according to the manufacturer’s instructions at 
The Binding Site, Birmingham (UK).
2.6 | Assay validation
All	analytical	procedures	were	adapted	from	Clinical	and	Laboratory	
Standards Institute (CLSI) guidelines. For the assessment of linear-
ity, 10 samples with varying C1- INH concentrations were generated 
by mixing a serum sample pool with known high C1- INH concen-
tration with an analyte- depleted serum sample pool. The observed 
concentrations were then plotted against the calculated expected 
concentrations.
The limit of blank (LoB) was determined by running analyte- 
depleted	serum	60	times.	Limit	of	detection	(LoD)	and	limit	of	quanti-
fication (LoQ) samples were generated by mixing unprocessed serum 
with analyte- depleted serum to give C1- INH concentrations of 0.1 and 
0.7 g/L, respectively. The LoD was calculated from the LoB and the 
standard deviation (SD) of 60 tests of the LoD sample. The LoQ was 
calculated from 40 replicates of the LoQ sample, and the mean, SD and 
percentage coefficient of variation (%CV) were calculated.
Assay	imprecision	was	assessed	by	measuring	the	C1-	INH	con-
centrations in five different pooled sera samples (up to 100 donors 
per pool). The samples included a sample below the normal refer-
ence interval (0.13 g/L), a sample within the range at the standard 
1/5 analyzer dilution (0.39 g/L), a sample within the range at the 
maximum	1/10	analyzer	dilution	(0.41	g/L),	plus	two	samples	−25%	
(0.16 g/L) and +25% (0.30 g/L) of the medical decision point (MDP, 
taken as the lower limit of the normal range 0.21 g/L). The samples 
were run in duplicate, with two runs per day using three reagent lots 
and five different analyzers over 21 consecutive days. The %CV and 
SD were determined for each source of variation.
Interference analysis was performed by spiking hemoglo-
bin (5 g/L), bilirubin (200 mg/L), chyle (1500 FTU), or triglyceride 
(1000 mg/dL) into sera samples with three different C1- INH con-
centrations (for hemoglobin, bilirubin, and chyle: 0.12, 0.23, and 
0.32 g/L; triglyceride; 0.11, 0.20, and 0.32 g/L C1- INH). Controls 
were	 generated	 by	 spiking	 samples	 with	 equivalent	 volumes	 of	
saline. The assay was deemed to have passed the interference as-
sessment if the C1- INH concentration after addition of the potential 
interfering substances was <±10% of the original value in the control 
sample.
2.7 | Normal adult reference interval
The central 95th percentile reference interval was established by 
measuring the C1- INH concentrations in serum samples taken from 
120 healthy adult blood donors. These results were used to calculate 
the central 95th percentile range.
2.8 | Assay comparison
To compare the Optilite C1- INH assay with an assay already used 
in a clinical laboratory, 260 samples sent for C1- INH investigation 
were assayed. These patients were undergoing investigation into 
the cause of their angioedema. The off- site laboratory results for 
C1- INH protein concentration were determined using a radial immu-
nodiffusion assay (RID, The Binding Site Ltd.).
2.9 | Comparison of C1- INH protein concentration 
with C1- INH functional activity
C1- INH functional activity was determined using the Berichrom C1- 
Inhibitor assay (Dade Behring, Germany). Optilite C1- INH testing was 
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performed at The Binding Site (Birmingham, UK). For the correlation 
between the Optilite C1- INH concentration and the functional C1- INH 
result, all samples with a result above the measuring range (>140% of 
the normal control) in the functional assay were removed from the 
analysis.
2.10 | Statistical analysis
All	graphs	and	statistical	analyses	were	generated	using	GraphPad	
Prism	version	5.04	or	Analyze-	it®	 for	Microsoft	Excel	programs.	A	
P < 0.05 was considered statistically significant.
3  | RESULTS
3.1 | Assay development
The C1- INH antiserum recognized C1- INH upon western blotting 
of pure protein, but did not detect potential interfering proteins 
(Figure 1, results shown for Factor XIa, Factor XIIa, Kallikrein, C1r, 
C1s, C2, C3c, C4, Factor B, and Properdin).
3.2 | Assay validation
C1- INH concentrations were linear in the assay between 0.07 and 
0.47 g/L, covering the assay measuring range (0.08- 0.44 g/L) at the 
standard 1/5 analyzer dilution (Figure 2; y = 0.98x + 0.01, r = 0.99). 
The LoB and LoD for the C1- INH assay were 0.006 and 0.011 g/L, 
respectively [LoD = LoB + (1.645 SD LLS) = 0.006 + (1.645 × 0.003)]. 
The LoQ was 0.067 g/L (SD- 0.003 g/L, %CV- 4.6%).
Assay	imprecision	was	calculated	within	run	and	between	runs,	
days, batches, and instruments using five samples with different C1- 
INH concentrations (Table 1). Percentage CVs within run, between 
runs, between days and between batches were all between 0.5% 
and 5.7%. The total assay imprecision was between 4.7% and 7.6% 
for all samples. The addition of chyle, hemoglobin, bilirubin, or tri-
glyceride caused minimal interference with the measurement of C1- 
INH at the concentrations tested (Table 2).
3.3 | Normal adult reference interval
Serum samples from 120 healthy adult donors were used to deter-
mine a 95th percentile reference interval for the automated C1- INH 
assay of 0.21- 0.38 g/L (median- 0.29 g/L, mean- 0.29 g/L). No signifi-
cant difference was observed between sexes.
3.4 | Assay comparison
The concentrations obtained using the Optilite C1- INH assay were 
compared to the C1- INH concentrations and C1- INH function results 
obtained from the clinical laboratory. There was a strong correlation 
between the C1- INH protein concentrations generated using the 
Optilite assay and the concentrations obtained using RID in the clinical 
laboratory (R2 = 0.94, P < 0.0001, slope y = 0.83x) with a mean bias of 
0.0096	g/L	using	the	Optilite	assay	(95%	CI	−0.04	to	0.06)	(Figure	3).
3.5 | Comparison of C1- INH protein concentration 
with C1- INH functional activity
There was also a significant correlation between the C1- INH con-
centration obtained from the Optilite assay and the C1- INH func-
tional measurements (P < 0.0001, R2 = 0.84) (Figure 4).
F IGURE  1 Assessment	of	C1-	INH	
antisera.	10%	SDS-	PAGE	gels	were	loaded	
with a protein ladder (lane 1) and various 
pure proteins; lane 2- C1- INH, 3- Factor 
XIa, 4- Factor XIIa, 5- Kallikrein, 6- C1r, 
7- C1s, 8- C2, 9- C3c, 10- C4, 11- Factor B, 
12-	Properdin.	A,	0.5	μg of each protein 
was added for western blotting with 
C1- INH antiserum. B, 2 μg of each protein 
was added for Coomassie blue staining
F IGURE  2 Linearity of the Optilite C1- INH assay. Ten samples 
were generated by diluting a serum sample with a high C1- INH 
concentration in a serum sample with a low concentration of 
C1- INH. Samples were run in triplicate and the mean result for 
each concentration was plotted against the expected C1- INH 
concentration. Identity line shown where y = x
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3.6 | Clinical utility of the C1- INH Optilite assay
When comparing patient diagnoses, four different groups are shown 
(Figure	5);	those	with	HAE	Type	I	(n	=	24),	HAE	Type	II	(n	=	3),	AAE	
(n	=	3),	and	those	with	unspecified	angioedema	(UAE)	not	diagnosed	
as	HAE	or	AAE	 (n	=	76).	There	was	100%	agreement	between	the	
two C1- INH protein concentration assays at determining whether 
patients had C1- INH concentrations below or above the lower limit 
of	the	respective	reference	ranges.	All	HAE	Type	I	and	AAE	patients	
tested here had C1- INH concentrations below the normal reference 
intervals,	whereas	no	UAE	patients	did.	As	expected,	the	three	Type	
II	HAE	patients	were	not	identified	using	either	protein	concentra-
tion assay, but had C1- INH functional measurements below the nor-
mal	range	of	the	assay,	along	with	all	HAE	Type	I	and	AAE	patients	
tested.
4  | DISCUSSION
In this study, we have described the development and validation of 
an automated assay for the measurement of C1- INH protein con-
centration on the Optilite turbidimetric analyzer. The assay allows 
the	rapid,	precise,	and	quantitative	evaluation	of	C1-	INH	over	a	wide	
measuring range, covering concentrations likely to be encountered 
in clinical practice. The assay was linear over the measuring range of 
0.08- 0.44 g/L at the standard 1/5 analyzer dilution, and was largely 
unaffected by common blood constituents.
Many	laboratories	currently	use	techniques	such	as	RID26 for the 
quantification	of	C1-	INH	protein	concentration.	This	technique	may	
TABLE  1  Imprecision of automated Optilite C1- INH assay
C1- INH 
Concentration (g/L)
Within- run Between- run Between- day Between- batch
Between- instru-
ment Total Precision
% CV SD % CV SD % CV SD % CV SD % CV SD % CV SD
0.127 1.9 0.00 5.7 0.01 4.7 0.01 0.6 0.00 2.5 0.00 7.6 0.01
0.165 3.2 0.01 4.1 0.01 4.9 0.01 1.6 0.00 2.5 0.00 7.1 0.01
0.289 1.7 0.00 2.3 0.01 4.3 0.01 1.4 0.00 2.0 0.01 5.1 0.01
0.393 1.6 0.01 1.9 0.01 4.4 0.02 1.5 0.01 3.3 0.00 5.1 0.02
0.418 2.0 0.01 1.8 0.01 3.8 0.02 0.5 0.00 1.7 0.01 4.7 0.02
Precision	was	assessed	in	serum	samples	with	five	different	C1-	INH	concentrations.	Each	sample	was	assayed	in	duplicate,	with	two	runs	per	day	over	
21	days—giving	a	total	of	84	readings	per	sample.	This	part	of	the	study	was	carried	out	using	three	reagent	lots	and	five	different	analyzers.
TABLE  2  Interference data for automated Optilite® C1- INH 
assay
Chyle Bilirubin Hemoglobin Triglyceride
Low 1.6% 8.9% 4.3% −3.5%
MDP 3.1% 0.9% 6.2% −1.7%
Normal range 1.3% 1.0% 3.5% −1.5%
Serum samples with three different C1- INH concentrations (one low 
concentration, one around the medical decision point (MDP) and one 
within the normal range) were spiked with one of four interferents or 
saline	 as	 a	 control.	 All	 samples	 were	 then	 run	 in	 the	Optilite	 C1-	INH	
assay. The results represent percentage change observed in the pres-
ence of the interfering substance.
F IGURE  3 Comparison of C1- INH concentration by Optilite and RID. The C1- INH concentration was measured using the Optilite assay, 
and compared to the radial immunodiffusion (RID) method used routinely in the clinical laboratory. Two hundred and sixty serum samples 
from	patients	with,	or	undergoing	investigation	for	angioedema	were	used.	Comparison	between	the	two	assays	was	assessed	using	A,	
Passing- Bablok analysis (identity line shown where y = x)	and	B,	Bland-	Altman	analysis	(solid	line	demonstrates	the	mean	difference	and	
broken	lines	show	the	limits	of	agreement,	−1.96	and	+1.96	standard	deviations)
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be laborious and time- consuming, and for RID the interpretation of 
results	is	potentially	subjective,	requiring	trained	staff	to	carry	out	
the analyses. The assay described here is automated, simple and has 
a	quick	 time	 to	 first	 result.	The	assay	has	 also	 fulfilled	 criteria	 for	
linearity, precision, and interference which are adpated from CLSI 
guidelines, making it an attractive alternative to other available 
methods. Using 120 healthy adult blood donors, a 95th percentile 
reference interval of 0.21- 0.38 g/L was established.
Here, we provide a comparison between the high- throughput, 
automated assay, and an existing method used routinely in the clinical 
laboratory. To ensure the results obtained in the Optilite assay were 
comparable to those generated using the predicate assay, a compar-
ison was performed using 260 samples sent for C1- INH investiga-
tion. These patients were undergoing investigation into the cause of 
their angioedema. The Optilite assay results correlated strongly with 
those generated with the predicate method.
All	patients	tested	with	Type	I	HAE	and	AAE	in	this	study	were	
identified as having C1- INH concentrations below this normal range. 
Timely diagnosis of these patients is crucial, as these disorders can 
be	fatal.	Studies	suggest	mortality	in	HAE	to	be	approximately	30%	
before	improvements	in	the	diagnosis	and	treatment	of	the	disease—
primarily due to asphyxiation caused by laryngeal edema.21,27,28 
Improvements	in	HAE	therapies	mean	that	acute	attacks	can	be	ef-
fectively treated either in hospital or at home and in those with a 
high	attack	 frequency	prophylactic	 therapy	has	been	shown	to	be	
effective	in	reducing	attacks.	Accurate	and	early	diagnosis	is	there-
fore key to ensuring these patients receive timely and appropriate 
care. C1- INH testing and achieving a definitive diagnosis is also im-
portant for the reimbursement of specific therapies in some coun-
tries,	 emphasizing	 the	 requirement	 for	 laboratory	 tests	 that	 aid	 in	
specific diagnoses.
The	three	Type	II	HAE	patients	tested	here	had	normal	pro-
tein concentrations of C1- INH by both the predicate assay and 
the Optilite assay. It is known that these patients have normal 
protein concentrations but reduced function, and functional 
C1-	INH	testing	 is	 therefore	required	to	 identify	 these	patients.	
As	 expected,	 the	 results	 provided	 from	 the	 clinical	 laboratory	
demonstrate these patients do indeed have greatly reduced C1- 
INH function.
As	a	consequence	of	uncontrolled	complement	activation,	serum	
C4	is	also	low	in	the	majority	of	patients	with	HAE15,23	and	AAE,29 and 
due to the ease, cost and availability of this assay, it is often used to 
F IGURE  5 C1- INH concentration 
and C1- INH functional activity in clinical 
samples. The C1- INH concentrations 
were measured using the Optilite assay 
(A)	and	radial	immunodiffusion	(RID,	B).	
The functional activity of C1- INH is also 
shown (C). Shaded areas represent the 
normal range of the assays
F IGURE  4 Correlation between C1- INH concentration and 
C1- INH functional activity. C1- INH concentration and functional 
activity were measured in serum samples (n = 199, samples with 
C1- INH function over the range of the assay (>140%) of the normal 
control were removed from this analysis). ▴ = 3 Type II hereditary 
angioedema	(HAE)	samples,	●	=	all	other	samples	(Type	I	HAE,	
acquired	angioedema	(AAE),	and	unspecified	angioedema	[UAE]).	
Results were analyzed using linear regression analysis
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“request	manage”	access	to	C1-	INH	assays	in	the	UK.26 However, sev-
eral studies have now shown that normal serum C4 does not always 
exclude	the	diagnosis	of	HAE.26,30 One recent study demonstrated low 
serum	C4	had	only	71%	sensitivity	for	HAE	diagnosis,	whereas	low	C1-	
INH	had	97%	sensitivity	for	Type	I	HAE26—demonstrating	the	impor-
tance of measuring C1- INH protein concentration to aid the diagnosis 
of these patients.
5  | CONCLUSION
In conclusion, the Optilite C1- INH assay provides a simple, rapid and 
precise method for the measurement of C1- INH in patient serum 
samples, and could be used to aid in the diagnosis of angioedema 
caused by C1- INH deficiencies.
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